



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

of 2

Complete if Known

Application Number	09/942,087
Filing Date	August 28, 2001
First Named Inventor	C. Case
Art Unit	1631
Examiner Name	John S. Brusca
Attorney Docket Number	S2-US5


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ²
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
JB	E1	WO 99/27092	06-03-1999	Prolifix Ltd.		
JB	E2	WO 01/04296 A1	01-18-2001	McGill Univ.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	---

*EXAMINER: Initial inference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute Reference Number/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

2

Complete if Known	
Application Number	09/942,087
Filing Date	August 28, 2001
First Named Inventor	C. Case
Art Unit	1631
Examiner Name	John S. Brusca
Attorney Docket Number	S2-US5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>JB</i>	F1	ALTINCICEK et al. "Interaction of the corepressor alien with DAX-1 is abrogated by mutations of DAX-1 involved in adrenal . . ." J. Biol. Chem. 275:7662-7667 (2000)	
<i>JB</i>	F2	COOK et al. "Three conserved transcriptional repressor domains are a defining feature of the TIEG subfamily . . ." J. Biol. Chem. 274:29500-29504 (1999)	
<i>JB</i>	F3	CRAWFORD et al. "Nuclear receptor DAX-1 recruits nuclear receptor corepressor N-CoR . . ." Mol. Cell. Biol. 18:2949-2956 (1998)	
<i>JB</i>	F4	ITO et al. "DAX-1 inhibits SF-1-mediated transactivation via a carboxy-terminal domain . . ." Mol. Cell. Biol. 17:1476-1483 (1997)	
<i>JB</i>	F5	LAI et al. "RBP1 recruits the mSIN3-histone deacetylase complex to the pocket of . . ." Mol. Cell. Biol. 21:2918-2932 (2001)	
<i>JB</i>	F6	LaPIERRE et al. "Identification of a novel transcriptional repressor encoded by human cytomegalovirus" J. Virology 75:6062-6069 (2001)	
<i>JB</i>	F7	MAXON et al. "Ash1p is a site-specific DNA-binding protein that actively represses transcription" Proc. Natl. Acad. Sci. USA 98:1495-1500 (2001)	
<i>JB</i>	F8	SABBATTINI et al. "Binding of Ikaros to the lambda5 promoter silences transcription . . ." EMBO Journal 20:2812-2822 (2001)	
<i>JB</i>	F9	ZAZOPOULOS et al. "DNA binding and transcriptional repression by DAX-1 blocks steroidogenesis" Nature 390:311-315 (1997)	
<i>JB</i>	G1	ZHANG et al. "A conserved alpha-helical motif mediates teh interaction of Sp1-like transcriptional represso . . ." Mol. Cell. Biol. 21:5041-5049 (2001)	

Examiner Signature	<i>John S. Brusca</i>	Date Considered	27 February 2004
--------------------	-----------------------	-----------------	------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.